Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Michelle L. Cloud"'
Publikováno v:
Clinical Pharmacology and Therapeutics. 52:307-313
Study objective: To determine if 150 mg nizatidine twice daily or 300 mg nizatidine at bedtime are similarly effective and to compare each dose with placebo in healing benign gastric ulcers and relieving peptic ulcer symptoms. Methods: This study was
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::536e2ba2b98ac93d658c0f1b047c533c
https://doi.org/10.1038/clpt.1992.146
https://doi.org/10.1038/clpt.1992.146
Autor:
Michelle L. Cloud, Walter W. Offen
Publikováno v:
Digestive Diseases and Sciences. 37:865-874
In a randomized, multicenter trial, nizatidine 150 mg or 300 mg, or placebo, was administered twice daily for six weeks to 515 patients with gastroesophageal reflux disease (GERD). Gelusil antacid tablets were taken as needed for pain. Significantly
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2bc19213a88357435b4812dbc1a7285b
https://doi.org/10.1007/bf01300384
https://doi.org/10.1007/bf01300384
Publikováno v:
Archives of Internal Medicine. 153:2449
Background: Nonsteroidal anti-inflammatory drug (NSAID) use is increasingly recognized as a major factor associated with peptic ulcer disease and complications. We undertook a multicenter, double-blind, placebocontrolled trial to evaluate efficacy an
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d7f2eecf1f5f7edb787aa8778a4c0512
https://doi.org/10.1001/archinte.1993.00410210073008
https://doi.org/10.1001/archinte.1993.00410210073008
Publikováno v:
Annals of the New York Academy of Sciences. 524:356-368
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8fa44475b0994cc889c1782bf36ad2ae
https://doi.org/10.1111/j.1749-6632.1988.tb38558.x
https://doi.org/10.1111/j.1749-6632.1988.tb38558.x
Publikováno v:
Clinical pharmacology and therapeutics. 46(3)
Nizatidine, a new H2-receptor antagonist for treatment of duodenal ulcer disease, was evaluated in a unique two-phase, placebo-controlled, randomized, double-blind, multicenter clinical trial. Patients received either 150 mg nizatidine twice daily or
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f39b967148b023deb7f9a554b790b626
https://pubmed.ncbi.nlm.nih.gov/2570656
https://pubmed.ncbi.nlm.nih.gov/2570656
Autor:
Albert L. Sheffer, E. R. Mcfadden, James Kemp, Diane S. Farlow, Michelle L. Cloud, Talmadge King, Elliott Middleton, Gregory C. Enas, Leonard C. Altman, David Tinkelman, Thomas Platts-Mills, Robert G. Townley
Publikováno v:
The American review of respiratory disease. 140(5)
LY171883 is a new selective LTD4/LTE4-receptor antagonist. To evaluate the efficacy of LY171883, we studied 138 nonsmoking asthmatic patients, 18 to 65 yr old, in a double-blind, randomized block-design study. All patients were required to demonstrat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5783f98f8465260613878330ba9d3ec0
https://pubmed.ncbi.nlm.nih.gov/2554766
https://pubmed.ncbi.nlm.nih.gov/2554766